Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases


(SEATTLE), February 4, 2020-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound TTHX1114.  Trefoil is developing products based on this engineered form of FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue. 

Follow Us
Join us on LinkedIn Follow us on Twitter